The biotech index behind the ALPS Medical Breakthroughs ETF (SBIO) surged over 10% in six trading days following its June 18 semi-annual rebalance, which added 37 companies and removed 15. Key contributors to the gain included Apogee Therapeutics, Definium Therapeutics, and Veradermics, with Definium rising 72% shortly after inclusion. The index tracks firms with drugs in advanced FDA trials and sufficient cash to sustain operations, highlighting how index rules can rapidly impact biotech portfolios. This sharp move illustrates the volatility and opportunity in small-cap biotech investing through ETFs like SBIO.
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
CHARBONE Corporation has increased its helium delivery fleet from one to five units to meet rising demand caused by global helium supply disruptions, notably from Qatar. This expansion supports North American customers in sectors like semiconductors ...
Citi has started coverage of Hikma Pharmaceuticals with a 'buy' rating and a £17 price target, highlighting the company's strategic shift towards differentiated products and US manufacturing investments. The broker sees a 14% potential share price re...
Xenon Pharmaceuticals is evolving into a late-stage, cash-rich neuroscience company with a validated Kv7 potassium channel platform. Its lead drug candidate, azetukalner, has shown strong effectiveness in treating refractory focal onset seizures and ...
